Press Releases

ELIAS Animal Health featured on Worldwide Business with kathy ireland®

Olathe, Kan., May 15, 2019 – ELIAS Animal Health, a Kansas City company dedicated to improving the treatment options for companion animals diagnosed with cancer, will be featured on Worldwide Business with kathy ireland®. Distributed internationally as sponsored content, you can view a highlight video below.      The full interview will air on the following channels: Americas: Fox Business Network May 19, 2019, 5:30 p.m. EST Europe & Africa: Bloomberg EMEA Saturday, May 18, 2019, 7:30 p.m. GMT Asia: Bloomberg Asia Sunday, May 19, 2019, 10:30 a.m. D.F. and 3:00 p.m. HKT

By |2019-05-16T21:06:56-06:00May 16th, 2019|Press Releases|0 Comments

ELIAS Animal Health Announces Positive Results in Treatment of Osteosarcoma in Dogs

Olathe, Kan., Oct. 25, 2018 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, announced results from its canine osteosarcoma immunotherapy trial at the 2018 Veterinary Cancer Society (VCS) Annual Conference. The study evaluating ELIAS’ Autologous Prescription Product, known as ECI® (ELIAS Cancer Immunotherapy) resulted in a median survival time (MST) of 415 days in animals completing therapy – compared to historical treatment outcomes associated with surgery alone (134 days1). These results will be included in the ELIAS submission to USDA-CVB during the fourth quarter. ELIAS intends to initiate a larger field safety and efficacy study in early 2019. “We are very encouraged by our osteosarcoma clinical trial results as we move towards commercialization of ECI® for the veterinary community, while continuing to explore our platform technology in other cancers such as lymphoma,” said Noe Reyes, D.V.M., ELIAS medical director. The trial [...]

By |2019-02-14T10:31:08-06:00October 25th, 2018|Press Releases|0 Comments

ELIAS Autologous Prescription Product Exceeds Expectations for Trial Safety and Efficacy

Olathe, Kan., July 31, 2018 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, shared promising preliminary canine osteosarcoma results for its cancer immunotherapy at the 2018 American College of Veterinary Internal Medicine (ACVIM) Forum in June. The study indicated its new ELIAS autologous cancer vaccine, featuring a patented combination of vaccine and T cell infusion approach, demonstrated impressive survival times and minimal side effects. This cancer immunotherapeutic is being distributed as an experimental product under 9 CFR 103.3 to veterinarians treating dogs diagnosed with cancer. Efficacy and safety have not been established. The results were presented by Brian Flesner, D.V.M., Dipl. ACVIM-Oncology, University of Missouri, and highlight continued progress within the immunotherapy arena for the treatment of canine cancer. One in four dogs will be impacted by cancer in their lifetimes and cancer is the No. 1 cause of death in [...]

By |2019-02-14T10:57:48-06:00July 31st, 2018|Press Releases|0 Comments

ELIAS Animal Health Cancer Immunotherapy Selected for State of the Art Presentation at VCS Mid‐Year Conference

Olathe, Kan., Feb. 12, 2018 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, has been selected by the Veterinary Cancer Society (VCS) for a “State of the Art” presentation at its Mid‐Year Conference in Anchorage, Alaska, March 10‐13. The mid‐year conference is focused on immunotherapy. Brenda Phillips, D.V.M., Dipl. ACVIM (Oncology) will present “T cell‐mediated immunotherapy for common canine cancers” during the state of the art presentation on Sunday, March 11. Dr. Phillips is a board‐certified specialist in medical oncology, practicing with Veterinary Specialty Hospital in San Diego, Calif. The clinical process, ongoing trials, management and experiences of this treatment being developed specifically for veterinary use in dogs will be discussed during the 30‐minute presentation. More data from the study is expected to be presented at the ACVIM Forum in June. ELIAS Animal Health has applied for conditional licensure of its [...]

By |2019-02-14T10:42:53-06:00February 12th, 2018|Press Releases|0 Comments

ELIAS Animal Health Adds Clinical Trial Site for ECI™ for the Treatment of Canine Osteosarcoma

ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, is offering a fourth site for its clinical trial to determine the safety and efficacy of ELIAS Cancer Immunotherapy (ECI™) as a treatment for newly- diagnosed appendicular osteosarcoma in dogs. The objective of this clinical trial is to determine whether ECI™ used in combination with surgery produces better outcomes than treatment with surgery alone. Efficacy will be determined by patient survival and comparing the outcomes to historical control data. The trial will be conducted at the Veterinary Specialty Hospital of San Diego. ELIAS Animal Health chief executive officer, Tammie Wahaus, shared a promising update on trial results to-date on Nov. 3, during the Collaborate2Cure series sponsored by Kansas City Area Life Sciences Institute and BioKansas. “Early clinical study results already show positive outcomes,” said Wahaus. “One patient, a 6-year old German Shorthaired Pointer, has [...]

By |2019-02-14T10:46:36-06:00November 15th, 2016|Press Releases|0 Comments

ELIAS Animal Health Announces First Patient Enrolled in Clinical Trial for ECI™ for the Treatment of Canine B-Cell Lymphoma

Olathe, Kan., Aug. 24, 2016 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, today announced the initiation of a clinical trial to determine the safety and efficacy of ELIAS Cancer Immunotherapy (ECI™), as a treatment for B-cell lymphoma in dogs. The majority of canine lymphomas are derived from B cells. While lymphoma is one of the most responsive cancers to chemotherapy, permanent cures in dogs are extremely rare and remissions are short-lived. There is a need for safer, more effective treatments for this disease. The objective of this clinical trial is to determine whether ECI™ used in combination with chemotherapy produces better outcomes than treatment with chemotherapy alone. Efficacy will be determined by patient survival and comparing the outcomes to historical control data. The trial will be conducted at the Kansas State University Veterinary Health Center. The ECI™ treatment protocol vaccinates [...]

By |2019-02-14T10:48:23-06:00August 24th, 2016|Press Releases|0 Comments

ELIAS Animal Health Names Ronald Schultz and Noe Reyes to Scientific Advisory Board

Olathe, Kan., September 1, 2015 - ELIAS Animal Health, a clinical stage development company advancing novel targeted T cell-based immunotherapy for the treatment of cancer in companion animals, today announced it has filled the remaining appointments to the company’s scientific advisory board with the additions of Ronald Schultz, PhD, and Noe Reyes, DVM. They join board chair Kevin Schultz, DVM, PhD, and Ralph Richardson, DVM, on the advisory board, which is tasked with offering strategic guidance on the advancement of therapies in development and exploring new therapeutic areas in which the company’s technology would be applicable. Dr. Ron Schultz is a recognized leader on veterinary vaccines, virology and immunology. He currently serves as professor and chair of the Department of Pathobiological Sciences at the School of Veterinary Medicine at the University of Wisconsin-Madison. His primary emphasis of research focuses on the pathogenesis of viral infections in large and companion animals. [...]

By |2019-02-14T10:51:46-06:00September 1st, 2015|Press Releases|0 Comments

ELIAS Animal Health Announces Start of Clinical Trial for ECI-OSA-11 for the Treatment of Canine Osteosarcoma

Olathe, Kan., Aug. 4, 2015 - ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, today announced the initiation of a clinical trial to determine the safety and efficacy of ECI-OSA-11, the company’s T cell-based immunotherapy for the treatment of osteosarcoma, a common form of canine cancer for which there is no cure. This fully-funded clinical trial will enroll dogs that have been diagnosed with osteosarcoma, but have not yet been treated for their cancer. The trial will be conducted at the University of Missouri, Columbia College of Veterinary Medicine. ECI-OSA-11 is a form of immunotherapy that involves treating the patient with its own cancer-specific “killer” T cells. The patient will have surgery to remove their osteosarcoma and then will be treated with ECI-OSA-11 to eliminate cancer cells that remain following surgery. The objective of this clinical trial is to determine whether ECI-OSA-11 [...]

By |2019-02-14T10:55:37-06:00August 4th, 2015|Press Releases|0 Comments